‘Shine a Light on HS’ is an initiative that will raise awareness on Hidradenitis Suppurativa and deliver important insights to help healthcare providers and policymakers to support patients that are affected by this condition.
Novartis, a leading global medicines company, today announced a ground-breaking partnership with the Emirates Dermatology Society (EDS) to tackle the urgent need for Hidradenitis Suppurativa (HS) awareness in the UAE. The collaboration aims to raise awareness of the condition and deliver critical insights to help healthcare providers and policymakers to support patients affected by this debilitating disease.
HS, a chronic skin condition characterised by painful lumps deep within the skin, affects an estimated 1 in 100 individuals worldwide. In the Asia Pacific, Middle East, and Africa (APMA) region, an estimated 80 percent of people affected still await a proper diagnosis.
Additionally, the average delay in diagnosing HS is up to a staggering seven years, with patients typically visiting, on average, five different physicians before receiving a formal diagnosis. However, due to limited awareness and understanding of HS, its true prevalence, both globally and regionally, remains uncertain.
The partnership between Novartis and EDS, under the initiative ‘Shine a Light on HS,’ represents an unprecedented opportunity to significantly improve the understanding, diagnosing, and management of this distressing condition. By harnessing the power of data, this initiative will equip healthcare professionals and policymakers with invaluable insights to make informed decisions for HS patients and drive positive change.
Mohamed Ezz Eldin, Head of Gulf Countries, Innovative Medicines at Novartis, said: “As part of our mission to reimagine medicine, we are committed to working extensively with stakeholders across the healthcare ecosystem to drive initiatives that will improve and extend people’s lives. Our partnership with the Emirates Dermatology Society aligns with our efforts to transform the landscape of awareness on HS in the UAE and beyond. Through this collaboration, we will revolutionise how HS is perceived, diagnosed, and treated. Together with the Emirates Dermatology Society, we strive to bring hope to the lives of HS patients and ensure their voices are heard.”
As part of this pioneering collaboration, Novartis and EDS will establish scientific, educational platforms targeting Dermatologists and patients in the UAE, fostering a deeper understanding of HS. By combining resources and expertise, both organisations will capture and generate local data on HS through Real World Evidence (RWE), empowering the medical community to make evidence-based decisions. Furthermore, widescale educational initiatives and platforms will be launched to raise awareness and promote understanding of HS among the general public.